ATE290910T1 - Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks - Google Patents

Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks

Info

Publication number
ATE290910T1
ATE290910T1 AT99935665T AT99935665T ATE290910T1 AT E290910 T1 ATE290910 T1 AT E290910T1 AT 99935665 T AT99935665 T AT 99935665T AT 99935665 T AT99935665 T AT 99935665T AT E290910 T1 ATE290910 T1 AT E290910T1
Authority
AT
Austria
Prior art keywords
lowering
production
medicinal product
eye pressure
adenosine antagonists
Prior art date
Application number
AT99935665T
Other languages
English (en)
Inventor
Mortimer M Civan
Richard A Stone
Claire H Mitchell
Kenneth A Jacobson
Original Assignee
Univ Pennsylvania
Us Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Us Government filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE290910T1 publication Critical patent/ATE290910T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
AT99935665T 1998-07-16 1999-07-15 Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks ATE290910T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9309798P 1998-07-16 1998-07-16
US12296599P 1999-03-03 1999-03-03
PCT/US1999/016211 WO2000003741A2 (en) 1998-07-16 1999-07-15 Methods for reducing intraocular pressure using a3-adenosine antagonists

Publications (1)

Publication Number Publication Date
ATE290910T1 true ATE290910T1 (de) 2005-04-15

Family

ID=26787065

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99935665T ATE290910T1 (de) 1998-07-16 1999-07-15 Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks

Country Status (8)

Country Link
US (2) US6528516B1 (de)
EP (1) EP1096975B1 (de)
JP (1) JP2003522729A (de)
AT (1) ATE290910T1 (de)
AU (1) AU765423B2 (de)
CA (1) CA2337499A1 (de)
DE (1) DE69924254D1 (de)
WO (1) WO2000003741A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
OA12147A (en) 1998-06-02 2006-05-05 Osi Pharm Inc PyrroloÄ2,3dÜpyrimidine compositions and their use.
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CN1491227A (zh) * 2001-02-05 2004-04-21 株式会社大V制药工厂 三唑并喹唑啉和吡唑并三唑并嘧啶衍生物、医药组合物、腺苷 a 3受体亲和剂、降眼压剂、预防和治疗青光眼的制剂及降低眼压的方法
DE60234118D1 (de) 2001-11-30 2009-12-03 Osi Pharm Inc Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
JP2005516917A (ja) 2001-12-12 2005-06-09 アメリカ合衆国 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法
JP4440642B2 (ja) 2001-12-20 2010-03-24 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピリミジンＡ２ｂ選択的アンタゴニスト化合物、それらの合成、及び使用
US7084128B2 (en) * 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
WO2008045330A2 (en) * 2006-10-06 2008-04-17 The Trustees Of The University Of Pennsylvania Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure
ES2531828T3 (es) * 2008-03-31 2015-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Derivados de purina como agonistas selectivos de los receptores A3 de adenosina
WO2010014921A2 (en) * 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
SG184221A1 (en) 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
US9227979B2 (en) 2012-01-25 2016-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fluorescent antagonists of the A3 adenosine receptor
PT2807178T (pt) 2012-01-26 2017-08-08 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
CN105188714A (zh) 2013-03-15 2015-12-23 伊诺泰克制药公司 眼用配制品
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
EP3402798B1 (de) 2016-01-14 2021-04-28 Handok Inc. Verbindungen als a3-adenosinrezeptor-antagonisten, verfahren zur herstellung davon und medizinische verwendung davon
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0688973B2 (ja) * 1987-03-12 1994-11-09 京都薬品工業株式会社 １，４−ジヒドロピリジン誘導体
EP2311806A3 (de) * 1996-01-29 2011-08-10 The United States of America, Represented by the Secretary, Department of Health and Human Services Dihydropyridin-, Pyridin-, Benzopyranon- und Triazolchinazolinderivate, ihre Herstellung und Verwendung als Adenosinrezeptorantagonisten
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
EP1096975A2 (de) 2001-05-09
US6528516B1 (en) 2003-03-04
AU765423B2 (en) 2003-09-18
WO2000003741A3 (en) 2000-09-28
US20030153626A1 (en) 2003-08-14
EP1096975B1 (de) 2005-03-16
CA2337499A1 (en) 2000-01-27
JP2003522729A (ja) 2003-07-29
DE69924254D1 (de) 2005-04-21
WO2000003741A2 (en) 2000-01-27
AU5109699A (en) 2000-02-07

Similar Documents

Publication Publication Date Title
ATE290910T1 (de) Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks
BRPI0418245B8 (pt) composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
EA200100678A1 (ru) N-уреидоалкил-пиперидины в качестве модуляторов активности рецепторов хемокинов
MX2007011300A (es) Solucion mejorada de bimatoprost oftalmico.
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
EE200200466A (et) 8,8a-dihürdroindeno[1,2-d]tiasooli derivaadid, mis on asendatud 8a-asendis, nende valmistamismeetodja kasutamine ravimitena, näiteks anorektiliste toimeainetena
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
KR880012227A (ko) 도파민 수용체 길항제의 신규사용법
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
PT1129096E (pt) Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
ATE487514T1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
ATE309796T1 (de) Verfahren zur behandlung von augenerkrankungen
BRPI0512525A (pt) canabidióis anormais como agentes para diminuir a pressão intraocular e fornecer efeito neuroprotetor ao olho
WO2002102978A3 (en) Human growth hormone antagonists
FR2767527B1 (fr) Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
DE60130030D1 (de) Verfahren zur behandlung von glaukom
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
NO20053876L (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties